In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

OS Therapies (NYSE:OSTX) is up ~65% in premarket trading Wednesday after releasing phase 2b data on OST-HER2 for prevention ...

With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...

OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.

Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

OS Therapies shares surged Wednesday after the biotech company reported positive data from a clinical trial for its cancer treatment OST-HER2. Shares of the N.Y., clinical-stage biotechnology company ...

Neoadjuvant SHR-A1811 showed similar pathologic complete response rates to the standard 4-drug regimen in patients with ...

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker ...

Under the deal, the companies will study ORIC-114, a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor, in combination with subcutaneous amivantamab, Johnson & Johnson's ...